FindTrial
Sign In

NL003

GENETIC5 trials

Sponsors

Beijing Northland Biotech. Co., Ltd.

Conditions

Arterial Occlusive DiseaseArteriosclerosis ObliteransCritical Limb Ischemia (CLI)Diabetic Foot Ulcer (DFU)Diabetic Foot Ulcer IschemicIschemiaPeripheral Arterial Disease(PAD)Peripheral Artery Disease

Phase 2

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
CompletedNCT01548378
Beijing Northland Biotech. Co., Ltd.Arterial Occlusive Disease, Ischemia, Peripheral Vascular Disease +1
Start: 2012-03-31End: 2014-06-30Updated: 2020-01-22

Phase 3

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)
CompletedNCT04274049
Beijing Northland Biotech. Co., Ltd.Arterial Occlusive Disease, Ischemia, Peripheral Vascular Disease +1
Start: 2019-08-28End: 2023-12-23Updated: 2024-09-20
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)
CompletedNCT04275323
Beijing Northland Biotech. Co., Ltd.Arterial Occlusive Disease, Ischemia, Peripheral Vascular Disease +1
Start: 2019-08-02End: 2024-06-03Updated: 2024-09-19
Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients
NCT05968118
Beijing Northland Biotech. Co., Ltd.Peripheral Artery Disease
Start: 2022-07-29End: 2023-10-31Target: 36Updated: 2023-08-01

Unknown Phase

Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
Enrolling by invitationNCT07023965
Beijing Northland Biotech. Co., Ltd.Arterial Occlusive Disease, Arteriosclerosis Obliterans, Critical Limb Ischemia (CLI) +4
Start: 2025-06-30End: 2027-12-31Target: 542Updated: 2025-07-11